颞浅动脉旁注射吡哆胺治疗糖尿病视网膜病变疗效观察  

Effect of para-temporal-superficial-artery injection of pyridoxamine on diabetic retinopathy

作　　者：陈丹娜[1] 陈敏[1] 许丽疆[1] 蔡福旭[1] 陈义[1] 

机构地区：[1]莆田学院附属医院眼科,福建莆田351100

出　　处：《中华实用诊断与治疗杂志》2014年第4期407-408,共2页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的探讨颞浅动脉旁注射吡哆胺在改善糖尿病视网膜病变患者症状、延缓糖尿病视网膜病变进展中的作用。方法糖尿病视网膜病患者60例(120眼)随机分为治疗组和对照组各30例(60眼),治疗组口服复方血栓通,并给予颞浅动脉旁注射吡哆胺2mL/次,1次/周,共6个月;对照组仅口服复方血栓通治疗。比较2组治疗前、后前房水终末糖基化产物(advanced glycation end products,AGEs)浓度及视网膜病变程度。结果治疗组治疗后前房水AGEs水平((0.12±0.09)μg/L)低于治疗前((0.26±0.06)μg/L)(P<0.05),对照组治疗后前房水AGEs水平((0.28±0.04)μg/L)高于治疗前((0.24±0.07)μg/L)(P<0.05),2组治疗后AGEs比较差异有统计学意义(P<0.05);注射后治疗组未发生不良反应,前房水内吡哆胺水平高于对照组(P<0.05)。结论颞浅动脉旁局部注射吡哆胺可降低眼内AGEs浓度,延缓糖尿病视网膜病情进展。Objective To study the effect of para-temporal-superficial-artery injection of pyridoxamine on relieving the symptoms and prolonging the progression of diabetic retinopathy. Methods Sixty patients （120 eyes） with diabetic retinopathy were divided into two groups, with 30 patients （60 eyes） in each group. Treatment group received oral administration of Xueshuantong and para-temporal-superficial-artery injection of 2 mL pyridoxamine once a week for totally 6 months, and control group received only oral administration of Xueshuantong. The concentration of advanced glycation end products （AGEs） and the degree of retinopathy were compared. Results AGEs level was （0. 12±0.09） /μg/L after treatment, lower than that before treatment （（0.26±0.06） μg/L） in treatment group （P〈0.05）, and was （0.28±0.04） /μg/L after treatment, higher than that before treatment （（0. 24± 0.07） μg/L） in control group （P〈0.05）. And there was a significant difference in AGEs level after treatment between two groups （P〈0.05）. No adverse reactions were found after injection. Pyridoxamine level in the anterior chamber was higher in treatment group than that in control group （P〈0.05）. Conclusions Para-temporal-superficial-artery injection of pyridoxamine can decrease AGEs level and delay the progression of diabetic retinopathy.

关 键 词：糖尿病视网膜病 吡哆胺 终末糖基化产物抑制剂 

分 类 号：R587.2[医药卫生—内分泌] R774.1[医药卫生—内科学]